US FDA Hopes ClinGen Database Will Spur Next-Gen Sequencing Products
The agency says it has evaluated ClinGen and will accept evidence based on the US National Institutes of Health-funded database for product applications. It hopes the use of the database will spur development of targeted treatments and diagnostics such as next generation sequencing tests.
You may also be interested in...
The promise of next-generation sequencing technology to help patients understand risk and target treatment for disease is high. US FDA is hoping to help accelerate practical advancements with the release of two final guidances addressing NGS technology and databases that aggregate genomic information.
As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers
Hold back on bragging about your emergency use authorizations until you have them in hand, says one expert after diagnostics company Bodysphere had to backtrack its EUA announcement due to a misunderstanding with the US FDA.